Skip to main content

Table 1 Patients characteristics at inclusion

From: Rituximab for auto-immune alveolar proteinosis, a real life cohort study

Patients

1

2

3

4

5

6

7

8

9

10

11

12

13

Age (year)

44

56

50

30

53

41

49

44

59

41

51

49

45

Gender

M

M

M

F

M

F

M

F

F

M

M

M

M

Duration of PAP (months)

38

12

12

29

64

50

6

32

9

15

45

20

51

Smoking status

Never

Never

Current

Current

Never

Never

Never

Never

Ex

Current

Ex

Ex

Current

Inhaled toxic

No

No

Yes

Yes

Yes

No

Yes

No

Yes

Yes

Yes

Yes

No

Previous therapy

No

WLL

GM-CSF

WLL

WLL

WLL

GM-CSF

WLL

GM-CSF

No

WLL

GM-CSF

WLL

WLL

WLL

GM-CSF

WLL

No

Initial Improvement with WLL

Np

No

No

Yes

Yes

Yes

Np

Yes

No

No

No

Yes

Np

Aggravation in the 3 month before RTX

Yes

No

Yes

Yes

No

Yes

Yes

No

Yes

Yes

Yes

Yes

Yes

Disease severity score

3

2

2

2

2

4

3

4

2

2

3

2

3

Anti GM-CSF titer before RTX

10,000

480

400

700

1000

200

400

400

40

300

300

800

4000

D(a-A)O2

At RTX injection

36

36

40

38

31

50

46

57

37

35

47

35

40

At M12

20

32

60

51

30

Na

35

60

38

Na

15

26

27

  1. PAP Pulmonary alveolar proteinosis, M Male, F Female, WLL Whole Lung lavage, RTX Rituximab, Na Not available, Np not performed
  2. For patients without dosage at rituximab injection, the last available concentration of anti-GM-CSF is reported